Abstract
2512 Background: Catumaxomab (anti-EpCAM x anti-CD3) is approved in the EU for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. Here we report the foll...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have